LDL receptor-related protein-1 regulates NFκB and microRNA-155 in macrophages to control the inflammatory response

Abstract

LDL receptor-related protein-1 (LRP1) is an endocytic and cellsignaling receptor. In mice in which LRP1 is deleted in myeloid cells, the response to lipopolysaccharide (LPS) was greatly exacerbated. LRP1 deletion in macrophages in vitro, under the control of tamoxifen-activated Cre-ER T fusion protein, robustly increased expression of proinflammatory cytokines and chemokines. In LRP1-expressing macrophages, proinflammatory mediator expression was regulated by LRP1 ligands in a ligand-specific manner. The LRP1 agonists, α 2 -macroglobulin and tissue-type plasminogen activator, attenuated expression of inflammatory mediators, even in the presence of LPS. The antagonists, receptor-associated protein (RAP) and lactoferrin (LF), and LRP1-specific antibody had the entirely opposite effect, promoting inflammatory mediator expression and mimicking LRP1 deletion. NFκB was rapidly activated in response to RAP and LF and responsible for the initial increase in expression of proinflammatory mediators. RAP and LF also significantly increased expression of microRNA-155 (miR-155) after a lag phase of about 4 h. miR-155 expression reflected, at least in part, activation of secondary cell-signaling pathways downstream of TNFα. Although miR-155 was not involved in the initial induction of cytokine expression in response to LRP1 antagonists, miR-155 was essential for sustaining the proinflammatory response. We conclude that LRP1, NFκB, and miR-155 function as members of a previously unidentified system that has the potential to inhibit or sustain inflammation, depending on the continuum of LRP1 ligands present in the macrophage microenvironment.LDL receptor-related protein-1 | tissue-type plasminogen activator | lipopolysaccharide | NFκB | microRNA-155

miR-155 Regulated Inflammation Response by the SOCS1-STAT3-PDCD4 Axis in Atherogenesis

“…PDCD4 and miR-155 played important roles in the regulation of inflammation response [24, 33–35]. Three PDCD4 siRNA oligos were transfected into RAW264.7 cells to evaluate the suppression effective of PDCD4 expression.…”

LRP1 modulates the microglial immune response via regulation of JNK and NF-κB signaling pathways

“…Although the specific LRP1 ligands that mediate the inflammatory responses remain to be identified, our results suggest that RAP may inhibit the binding of ligands to LRP1 and therefore trigger microglial activation. Indeed, a previous study has shown that the LRP1 agonist attenuated the expression of pro-inflammatory mediators even in the presence of LPS, while the antagonist and LRP1 antibody that block its function had an opposite effect in macrophage [56]. Identifying specific LRP1 ligands that are involved in the regulation of microglial activation might provide a novel target for AD therapy.…”

Microglial LRP1 modulates neuroinflammation via control of the NF-κB pathway in autoimmunity

“…However, our group and others have shown that LRP1 also regulates the activation of the inflammatory NF-κB signaling pathway 134,137 . In this work, I show for the first time that LRP1 can inhibit the MyD88 pathway downstream of the TLR signaling pathways.…”

“…In a sepsis model of LPS injection, peripheral macrophage LRP1 deficient animals showed decreased survival rates and corresponding increased systemic amounts of circulating TNFα and CCL3 137 . There was also increased IL-6 and iNOS mRNA 27 expressed in the organs of these mice.…”

“…There was also increased IL-6 and iNOS mRNA 27 expressed in the organs of these mice. Inhibiting LRP1 through pharmacological inhibition with its antagonist, RAP, also increased the production of proinflammatory cytokines in bone marrow macrophages 137 . Independently, LRP1-deficient BMDM showed increased cellular homing and migration, as they secrete increased levels of CCL2 and CCL3 in response to LPS stimulation, and LRP1-deficient monocytes also increase migratory activity in a model of pancreatic cancer 138 .…”